Brief: Aurobindo Pharma Says Co's Subsidiary Curateq Biologics Enters Marketing And Distribution Agreement With STADA Arzneimittel AG
25/03/2026 11:29
March 25 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: CO'S SUBSIDIARY CURATEQ BIOLOGICS ENTERS MARKETING AND DISTRIBUTION AGREEMENT WITH STADA ARZNEIMITTEL AG Source text: ID:nBSE2slBZl Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11